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The EGF-TM7 receptor CD97 shows different features of expression and function in muscle 
cells compared to hematopoetic and tumor cells. Since the molecular function and regulation 
of CD97 is poorly understood, this study aimed at defining its basal transcriptional regulation 
in smooth muscle cells (SMCs).  
The computational analysis of the CD97 5’-flanking region revealed that the TATA box-
lacking promoter possesses several GC-rich regions as putative Sp1/Sp3 binding sites. 
Transfection studies with serially deleted promoter constructs demonstrated that the minimal 
promoter fragment resided in the –218/+45 region containing one out of five identified GC-
boxes in the leiomyosarcoma cell line SK-LMS-1 and human bronchial smooth muscle cells 
(HbSMCs). Mutation of the most proximal GC-site in CD97 reporter gene constructs caused a 
significant decrease in promoter activity. Gel shift assays and chromatin immunoprecipitation 
revealed that Sp1 and Sp3 bound specifically to the most proximal GC-site. Furthermore, we 
showed that Sp1 and Sp3 over-expression activates CD97 promoter activity in HEK 293 cells.  
Our data characterize for the first time the activity of the human CD97 promoter which is 













CD97 belongs to a family of G-protein coupled receptors (GPCRs) with an unusual large N-
terminal extracellular domain (LNB-TM7) (Kwakkenbos et al., 2004; Stacey et al., 2000) and 
is the founding member of a small subfamily, the EGF-seven-transmembrane (EGF-TM7) 
receptors (Eichler et al., 1994; Hamann et al., 1995). It consists of a variable number of N-
terminally located EGF-domains, a long extracellular stalk, the TM7 and a short intracellular 
region. Alternative splicing results in three isoforms containing three, four or five EGF-
domains.  
CD97 shows interesting features in the expression pattern in different cell types. We 
described CD97 expression in cells of the hematopoetic system and detected CD97 over-
expression in tumor cells of different origin (Aust et al., 2002; Steinert et al., 2002). 
Moreover, CD97 can be proven in smooth muscle cells of the lung, gastrointestinal tract, 
urinary bladder and uterus (Aust et al., 2006). Surprisingly, vessels are heterogeneous: venous 
smooth muscle cells strongly express CD97, whereas elastic arteries are nearly CD97 
negative. Furthermore, CD97 heterogeneity was observed during smooth muscle cell 
transformation. All leiomyomas and 9 out of 21 leiomyosarcomas were CD97 positive (Aust 
et al., 2006). The disability of muscular CD97 to bind the ligand CD55 implicates another 
function in this cell type (Wobus et al., 2004) as the suggested role as an adhesion molecule 
(Hamann et al., 1996) in tumor cells where CD97 promotes migration capacity (Galle et al., 
2006; Steinert et al. 2002). Based on these findings, we are eminently interested in CD97 
regulatory mechanisms in SMCs.  
At present, no information regarding the basal or tissue-specific transcriptional regulation of 
any human EGF-TM7 receptor is available. Detailed sequence analysis of the CD97 5’-
flanking region revealed the presence of several GC-rich boxes, putative binding sites for the 
Sp family of transcription factors. Mithramycin interferes with the binding of Sp1 
transcription factors to GC-rich promoter regions in-vitro (Blume et al., 1991). We observed 
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decreased CD97 promoter activities as well as mRNA expression levels after mithramycin 
treatment of SMC cultures (unpublished data) which might be an indication for a CD97 gene 
regulation by Sp transcription factors. The Sp transcription factor family belongs to the 
conserved zinc finger DNA-binding domain proteins that recognize the DNA-binding motifs 
GC-box (GGGCGGG) and GT-box (GGTGTGGGG) (Suske, 1999). They are important for 
the expression of many different housekeeping genes as well as tissue-specific genes 
(Bouwman and Philipsen, 2002) that generally do not contain TATA- or CAAT-boxes in their 
proximal promoters. Several Sp proteins (Sp1-Sp8) have been identified (Bouwman and 
Philipsen, 2002; Suske et al., 2005). Whereas most Sp proteins show tissue-restricted 
expression patterns, Sp1 and Sp3 are ubiquitously expressed and compete for common target 
sequences (Shin et al., 2005). Sp1 is well known as a transcriptional activator, whereas Sp3 
can be either a transcriptional activator or repressor of Sp1-mediated transcription, depending 
on the promoter context and cell type (Majello et al., 1997). 
Here, we provide evidence that one of the identified GC-rich sites within the CD97 promoter 
is functional active by binding Sp1 as well as Sp3 in SMCs. This is the first study providing 
comprehensive information on the structure and features of the human CD97 promoter as well 
as a general molecular mechanisms by which the human CD97 gene expression is regulated. 
 
2. Materials and Methods 
2.1. Construction of plasmids for promoter analysis 
Progressive deletion constructs of the human CD97 promoter region were generated from a 
3116 bp PCR fragment of the human CD97 5’-flanking region (Wobus et al., 2006) and 
cloned into the KpnI and NheI site of the promoterless firefly luciferase reporter vector pGL-3 
basic (Promega GmbH, Mannheim, Germany). All nucleotide numberings are relative to the 
translation initiation codon (A=0). Primers used for amplification are listed in table 1. For 
amplification, we used high fidelity PCR enzyme mix (Fermentas GmbH, St. Leon-Rot, 
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Germany) and PCR conditions for long fragment amplification. Each construct was 
sequenced from both ends to confirm the correct fidelity. The expression vectors pN3/Sp1 and 
pN3/Sp3 were kindly provided by G. Suske (Philipps University, Marburg, Germany). 
 
2.2. 5’ RACE 
To determine the transcription start of the CD97 gene, 5’ RACE (Roche Diagnostics GmbH, 
Mannheim, Germany) was used according to the instruction manual. Briefly, mRNA from 
SK-LMS-1 cells was transcribed into cDNA with a CD97 specific revers primer HCD97r34 
(Tab. 1). After adding a 3’ poly (A) tail, amplification was carried out using an Oligo dt-
anchor primer and a nested CD97 specific primer HCD97r38 (Tab. 1). The PCR product was 
cloned into pGEM-T vector (Promega) and subsequently sequenced. 
 
2.3. Computational identification of transcription factor binding sites 
Computational binding site detection was performed to select a likely candidate for CD97 
regulation. In an initial pattern matching, using patch and TRANSFAC 6.0, several GC-rich 
boxes were identified. To strengthen the prediction we applied alternative methods and used 
alternative data resources. Weight matrix matching was performed using the match web 
interface at www.biobase.de and our implementation of the same algorithm (Kel et al., 2003) 
called pwmatch. Sp1 and Sp3 binding profiles were taken from TRANSFAC 6.0 and 
JASPAR 2005. The high scoring hits selected for site mutation studies are given in table 2. 
 
2.4. Site-directed mutagenesis   
Site-directed mutagenesis of potential Sp1/Sp3 binding sites in the CD97 promoter region 
(Tab. 1, 2) was carried out using the QuickChange site-directed mutagenesis kit (Stratagene 
Europe, Amsterdam, The Netherlands). 
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2.5. Cell culture, transient transfection and reporter gene assay 
The leiomyosarcoma cell line SK-LMS-1 and the embryonic kidney cell line HEK293 were 
obtained from American Type Culture Collection (ATCC, Rockville, MD). Human bronchial 
smooth muscle cells (HbSMC) were purchased from PromoCell GmbH (Heidelberg, 
Germany).  
Transfection experiments were performed in 24-well plates using Lipofectamine 2000 
(Invitrogen, GmbH, Karlsruhe, Germany). 200 ng of the various CD97-pGL-3 constructs 
were co-transfected with 10 ng of the Renilla reference plasmid pRL-null (Promega) to 
normalize the variations in transfection efficiency. Each plasmid was transfected in duplicate 
in at least four independent experiments. Fresh media was replaced 24 h later.  
Cells were lysed 48 h post-transfection in passive lysis buffer (Promega). The luciferase 
activity was determined using 40 µl of cell extract with the dual luciferase assay system 
(Promega). The luciferase activity was normalized to the Renilla activity and expressed 
relative to the activity of the empty pGL-3 plasmid. 
To determine the significance of data differences, an unpaired t test was used and a p value of 
less than 0.05 is considered to be significant. 
 
2.6. Electrophoretic Mobility Shift Assay (EMSA) 
Oligonucleotide probes of the five predicted GC-boxes (Tab. 1) were radiolabeled using T4 
polynucleotide kinase in the presence of [γ-32P]ATP and purified using the Nucleotide 
Removal Kit (Qiagen GmbH, Hilden, Germany). Nuclear extracts from SMCs were prepared 
according to the method of Schreiber et al. (1989). For the binding reaction nuclear extracts 
with ~5 µg protein were incubated for 15 min at room temperature in 10 mM Tris pH 7.5, 0.5 
mM EDTA, 1 mM MgCl2, 50 mM NaCl, 0.5 mM DTT, 6% glycerol and 0.75 µg of 
polydeoxyinosinic-deoxycitidylic acid (poly dI-dC; Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany) in a total volume of 10 µl. For supershifts, Sp1 and Sp3 specific 
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antibodies (sc-420, sc-644, Santa Cruz Biotechnology, Heidelberg, Germany) were incubated 
with protein mixtures prior to probe addition. Specificity of binding was controlled by the 
addition of 50 fold excess of cold competitor DNA to either wt or mutant Sp1/Sp3 sites of the 
CD97 promoter (Tab. 1). After probe addition, reactions were incubated for 20 min at room 
temperature and than separated on a 5% native polyacrylamide gel at room temperature. Gels 
were visualized using a FLA-3000 Fujifilm phosphorimaging system (Fuji, Düsseldorf, 
Germany). 
 
2.7. Chromatin immunoprecipitation assay (ChIP)  
ChIP assays were performed using a kit from Upstate (Lake Placid, NY, USA). All buffers 
contained 1 mM PMSF as well as Complete Protease Inhibitor Cocktail (Roche). 1x106 SMCs 
were fixed in a final concentration of 1% formaldehyde for 10 min at 37oC. Chromatin was 
sheared by sonication (Bandelin Sonoplus, Berlin, Germany) four times for 10 s, yielding 
DNA fragments of 200-800 bp. After preclearing with DNA- and albumin-blocked Protein A-
agarose for 30 min at 4oC, the samples were incubated overnight with 2 µg Sp1, Sp3 or 
control IgG antibody (DakoCytomation GmbH, Hamburg, Germany) with rotation at 4oC and 
precipitated with salmon sperm DNA-Protein A agarose for 1 h at 4oC. To reverse cross-links, 
chromatin complexes including input samples were incubated in 5 M NaCl at 65oC for 4 h, 
resuspended in Tris-EDTA proteinase K buffer for 1 h at 45oC and purified using a PCR 
purification kit (Qiagen). PCR amplifications were conducted using the CD97 promoter-
specific primers as indicated in table 1. Samples from at least three independent 





3.1. Cloning and characterization of the human CD97 promoter 
A comprehensive computational analysis of the human CD97 5’-flanking region from -3071 
to +45 relative to the CD97 translation start sequence did not show putative TATA or 
CCAAT boxes but revealed the presence of five GC-rich boxes, potential binding sites for 
Sp1 and  Sp3 transcription factors (Fig. 1A; Tab. 2).  
To precisely determine the transcription start site in the flanking region of the CD97 gene, 5’ 
RACE analysis was carried out using total RNA from SK-LMS-1 cells. Sequencing of the 
RACE products revealed that transcripts are initiated from a site 78 nt upstream of the ATG 
translation initiation codon. 
A 5’-flanking region fragment spanning nucleotides from – 3071 to +45 relative to the CD97 
translation start was cloned recently and displayed promoter activity in SW480 and DLD-1 
colorectal tumor cells (Wobus et al., 2006). To identify the sequence that is necessary for 
basal transcription of CD97 in SMCs, we examined the ability of various 5’ deletions of that 
construct to drive luciferase expression in the promoterless pGL-3 plasmid (Fig. 1B). Each 
construct drove luciferase transcription in HbSMCs and SK-LMS-1 cells. The pGL-3 empty 
plasmid served as a negative control. The longest promoter construct (–3071/+45) containing 
all five identified potential Sp1/Sp3 sites resulted in a moderate luciferase expression (Fig. 
1B). The -2101/+45 construct showed a higher promoter activity, but further deletion of the 5’ 
sequence to -1801/+45 and –1151/+45 resulted in decreased activities. Interestingly, the 
sequence –218/+45 carrying one Sp1/Sp3 site showed the highest level of expression, 
whereas the activity is almost completely abrogated at -111/+45 lacking GC-sequences (Fig. 
1B). The ratio between the various 5’ deletion constructs was similar in both cell lines with 
higher promoter activities in the SK-LMS-1 leiomyosarcoma cells. 
          
           Figure 1 
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3.2. Functional characterization of Sp1/Sp3 for the CD97 promoter activity 
To investigate the role of the GC-rich sites in the CD97 promoter in detail, site-specific 
mutagenesis for each site was performed. The luciferase activities in the mutated reporter 
constructs were compared with corresponding wildtype constructs which was the -2101/+45 
construct for the sites 1-4 and the –3071/+45 construct which contains also the site 5 located 
at –2317, respectively (Fig. 1C). Mutation of the most proximal GC-site 1 at -122 caused an 
almost complete abrogation of promoter activity in both cell lines. Mutation of the other 
potential Sp1/Sp3 sites did not cause significant changes in the promoter activities (Fig. 1C).
           Figure 1 
 
3.3. Sp1/Sp3 transcription factors bind to the CD97 promoter in-vitro and in-vivo 
To test specific binding of Sp1 and Sp3 to the identified GC-rich boxes in-vitro, we 
performed EMSAs using end-labeled double-stranded probes covering the potential binding 
sites within the CD97 promoter as indicated in Tab. 1. Except for GC-site 4, shifted DNA-
protein complexes were observed after incubation with nuclear extract from SMCs similar to 
those obtained with a GC-consensus-oligo as representatively shown for the GC-site 1 (Fig. 
2A). The binding was specific as shown by inhibition with an excess of unlabeled probe 
whereas the mutated oligos did not alter the DNA-protein binding.  
To determine whether these bands were DNA-Sp1 or DNA-Sp3 complexes, we used an 
interference assay with specific antibodies. The upper band was supershifted by the anti-Sp1 
antibody and the lower band by the anti-Sp3 antibody (Fig. 2B). We concluded that the upper 
band was a DNA-Sp1 complex and the lower band was the DNA-Sp3 complex, respectively. 
To examine whether Sp1 and Sp3 in fact bind to the CD97 promoter in-vivo, we performed 
ChIP with anti-Sp1 and anti-Sp3 antibodies in SMCs. A 230 bp DNA fragment covering the 
first GC-site at –122 was amplified by PCR immunoprecipitated with anti-Sp1 as well as anti-
Sp3 antibodies (Fig. 2C). The same band was obtained in the input DNA, whereas the normal 
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IgG control immunoprecipitates did not show a signal. Amplification with primers covering 
the other potentially Sp1/Sp3 binding sites produced no specific bands (not shown). 
These results indicate that Sp1 as well as Sp3 bind specifically to one of the identified GC-
rich sites within the CD97 proximal promoter in-vivo and that the other sites are obviously 




3.4. Sp1 and Sp3 activate CD97 promoter activity and expression 
After having determined that Sp1 and Sp3 can bind to the CD97 promoter and that this 
interaction is essential for basal promoter activity in SMCs, we examined whether Sp1 and/or 
Sp3 can directly activate the CD97 promoter in co-transfection experiments in HEK293 cells. 
The endogenous Sp1/Sp3 expression levels are low in HEK293 cells, therefore they can be 
used for co-transfection of Sp1/Sp3 with promoter reporter gene constructs (Banks et al., 
1999).  
Figure 3 presents the increase of low basal CD97 promoter activities after co-transfection 
with a Sp1 or Sp3 expressing plasmid in comparison to the empty vector pN3 control, 
suggesting that both factors act as transcriptional activators on CD97 promoter activities. 
Expression of Sp1 and Sp3 together did not result in an additive effect of activity increase 
(not shown). Co-transfection of Sp1 or Sp3 with the GC-site 1 mutated construct had no effect 
on CD97 promoter activity (Fig. 3) which emphasizes the importance of this Sp1/Sp3 site for 
CD97 promoter regulation.  
Figure 3 
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4. Discussion 
In the present study, we characterized the 5’-flanking region of the human CD97 gene as an 
initial step in understanding the regulation of CD97 in SMCs. We showed that Sp1 and Sp3 
transcription factors bind directly to the CD97 promoter and upregulate its activity. Of the 
five identified Sp1/Sp3 binding sites in a 3116 nt CD97 promoter region, the most proximal 
site relative to the translation start codon is critical for maintaining basal promoter activity. In 
linking the expression of CD97 to the activity of a specific family of transcription factors in 
human cells, we believe this is the first description of one mechanism controlling the 
expression of a human EGF-TM7 molecule. 
A comprehensive computational analysis revealed the absence of canonical TATA and 
CCAAT boxes in the 5’-flanking region of the CD97 gene. In fact, typical TATA and 
CCAAT boxes are also absent in numerous human G protein-coupled receptor genes, 
including the alpha1β-adrenergic receptor, glucagon receptor, glucagon-like peptide receptor, 
growth hormone-releasing hormone receptor gene and the secretin receptor genes (Pang et al., 
2004).  
However, we identified five GC-rich sites in the 3116 nt CD97 promoter region. The presence 
of GC-rich sequences within the 5’-flanking region is a feature of TATA-less genes, and the 
expression of such genes is regulated by members of the Sp-family (Philipsen and Suske, 
1999; Suske, 1999). It has been proposed that many TATA-less and GC-rich promoters bind 
one or more Sp1 molecules to recruit specific cofactors such as TATA-binding protein-
associated factors, which subsequently interact with transcription factor IID (TFIID) 
comprising TATA box-binding protein (TBP) and a number of TBP-associated factors to 
initiate gene transcription (Pang et al., 2004; Papadodima et al., 2005). 
To get an indication whether the GC-rich sites influence CD97 transcriptional regulation, we 
treated cell cultures with mithramycin, a cell-permeable agent that binds to GC-rich DNA 
sequences and that is frequently used to explore the sequence dependency of DNA-binding 
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factors (Liu et al., 2006). Since CD97 promoter activities as well as mRNA expression levels 
were decreased by mithramycin in SMCs, we studied the GC-sites in more detail using 
reporter gene assays as well as gelshift and ChIP analysis. 
The CD97 promoter reporter analysis using 5’ deletion constructs did not reveal a gradual 
decrease in promoter activity dependent on the GC-rich sites. These observations imply that 
also other unidentified positive/negative factors are effective in the proximal promoter of the 
CD97 gene (Shin et al., 2005). The construct -218/+45 carrying one GC-site showed the 
highest promoter activity whereas activity is almost abolished in the -111/+45 construct 
lacking GC-sequences. It is likely that further upstream located transcription factor bindings 
influence the CD97 promoter activity also in an inhibiting manner and act contrary to 
Sp1/Sp3. Generally, one or more transcription factors recruit specific proteins to 
cooperatively mediate the regulation of a target gene. There may also be competitive binding 
when multiple transcription factors simultaneously interact with the promoter region of a 
target (Wang et al., 2007).  
To investigate which of the predicted Sp1/Sp3 sites is functional relevant, we performed 
reporter gene assays with CD97 promoter constructs each with a mutated binding site. 
Interestingly, mutation of the most proximal site at –122 caused a significant decrease in 
promoter activity in comparison to the -2021 nt wildtype construct.  
Although Sp1 has been found to be expressed in a great variety of cell types, its function can 
be regulated through several different mechanisms and these differences could explain its 
involvement also in the tissue-specific promoter modulation. The Sp1/Sp3-dependent 
transcriptional regulation of CD97 in SMCs but not in colorectal tumor cells (own 
unpublished data) is a further example. Differences in localisation, biochemical modification 
and ligand binding of CD97 in SMCs suggest a different function and regulation from that at 
the cell surface of leukocytes and tumor cells (Wobus et al., 2004). The definition of CD97 
regulatory processes in SMCs is also important with respect to a potential involvement in 
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pathological processes as in vascular disorders. Interestingly, there is evidence that Sp1-
dependent mechanisms may be responsible for activation of genes characteristic of 
phenotypically modulated SMCs, such as the constitutive expression of platelet-derived 
growth factor (PDGF)- β chain gene during mouse development or smooth muscle myosin 
heavy chain (MHC) in neointimal SMCs after ballon injury in the rat aorta (Owens et al., 
2004). Sp1 was shown to have an anti-mitogenic, pro-apoptotic role in SMCs of the artery 
wall in atherosclerosis and restenosis (Kavurma and Khachigian, 2003). 
To evaluate whether increased levels of Sp1 and/or Sp3 would increase CD97 promoter 
activity, we co-transfected CD97 promoter constructs with Sp1 or Sp3 expression vectors in 
HEK293 cells which express low endogenous levels of Sp proteins (Banks et al., 1999) and 
can therefore be used for such Sp1/Sp3 over-expression experiments. Since dose-response 
studies have indicated that the Myeloid elf-1-like factor (MEF) and involucrin gene promoter 
activity is directly related to the concentration of Sp1 expression plasmid (Banks et al., 1999; 
Koga et al., 2005), we accomplished co-transfections of either Sp1 or Sp3. We demonstrated 
that both Sp1 and Sp3 can activate CD97 promoter activity in all constructs carrying at least 
the GC-box at the –122 site. Over-expression of Sp1 and Sp3 together did not show an 
additive effect which is in accordance with the assumption that both proteins bind to identical 
sequences (Suske, 1999). We showed that Sp3 acts as transcriptional activator, like Sp1, in 
the proximal region of the CD97 promoter. This suggests that Sp1 and Sp3 cross-regulate the 
expression of each other which could be explained by the fact that the Sp3 protein is able to 
bind within the Sp1 promoter (Shin et al., 2005). Although Sp1 and Sp3 can bind to the same 
GC-rich box, Sp3 was originally found to suppress Sp1-mediated activation by binding to the 
this sequence, thereby preventing Sp1-binding and activation. However, whether Sp3 acts as 
an activator or a suppressor of Sp1-mediated activation depends on the cellular conditions 
(Sato and Furukawa, 2004). The interaction between CD97 and Sp1 might affect other 
transcription factors which are important for basal and/or induced promoter activity (Shimada 
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et al., 2001). A large number of Sp1-interacting proteins have been identified. The interaction 
of Sp1 and MyoD is also important for the expression of various muscle-specific genes (Sato 
and Furukawa, 2004). 
In summary, this is the first report showing the transcriptional regulation of CD97 by Sp1/Sp3 
transcription factors in SMCs. Further on, it will be important to analyze other transcription 
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Fig. 1: CD97 promoter activities of wildtype and GC-box mutated luciferase reporter 
constructs in SK-LMS-1 cells and HbSMCs. 
A) Depiction of the identified GC-boxes in the CD97 5’ flanking region. 
B) Basal CD97 promoter activities of different 5’ deletion constructs. Luciferase activity was 
measured in cell lysates and normalized to the corresponding pRL-null activity. Data 
represent means ± SEM of the fold increase in luciferase activity as compared to empty pGL-
3 of at least four independent experiments.  
C) Effect of mutation of each Sp1/Sp3 binding site on CD97 promoter activities. Activities of 
constructs with mutated GC-sites 1 to 4 (filled box) were compared with activities of the wt  
–2101/+45 construct and activity of the construct with mutated GC-box 5 was compared with 
the wt –3101/+45 construct. Data represent the means ± SEM of at least four independent 
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experiments. Asterisks indicate significant difference (p < 0.05) between the wt -2101/+45 
and the mutated construct. 
 
Fig. 2: Sp1 and Sp3 bind to the CD97 promoter in-vitro and in-vivo in SMCs as 
representatively shown for SK-LMS-1 cells. 
A) In-vitro binding analysis by EMSA was carried out using radiolabelled oligonucleotides 
against a GC-consensus sequence (GC), and either the wildtype or mutant sequence of the 
Sp1 sites 1 to 5 in the human CD97 promoter with 5 µg nuclear extract of SK-LMS-1 cells in 
the absence (-) or presence 50-fold cold competitor oligonucleotides. Arrows indicate specific 
DNA-protein complexes for Sp1 and Sp3, respectively, whereas the asterisks represent 
nonspecific binding.  
B) For supershift experiments, 2 µg of antibodies complentary to Sp1 and Sp3 were 
preincubated with SK-LMS-1 nuclear extract before the addition of the radiolabelled wildtype 
GC-box 1 probe. Supershifted bands were detected for Sp1 (lane 2) as well as Sp3 (lane 3). 
C) ChIP assay from SK-LMS-1 cells with Sp1 and Sp3 antibodies. PCR was performed with 
primers amplifying a Sp1/Sp3-binding site containing fragment at –122 in the CD97 
promoter. A 230 bp DNA fragment was obtained in the Sp1 and Sp3 precipitated samples as 
well as the input DNA which corresponds to the chromatin fragments before 
immunoprecipitation, whereas no band was apparent in the normal IgG control 
immunoprecipitation. 
 
Fig. 3: CD97 promoter activity is increased by Sp1 or Sp3 over-expression, respectively. 
HEK293 cells were co-transfected with 200 ng of the CD97 promoter reporter constructs 
together with 200 ng of Sp1 or Sp3 expressing pN3 vector. As an uninduced control, the 
reporter constructs were co-transfected with the empty vector pN3. The GC-mutation is 
represented as filled box in the –2101/+45 construct. Luciferase activity was measured in cell 
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lysates and normalized to the corresponding pRL-null activity. Data represent the means ±  
SEM of the fold increase in luciferase activity as compared to the empty vector pGL-3 of at 












Tab. 1: Primers used for PCR procedure in the experiments 
Name Sequence 5’ –3’ 
For 5’ RACE  
HCD97r34 aga cac aga atg cga gaa aga 
HCD97r38 tgc cgg cag gag cgg cag ggg 
For generation of the 5’ stepwise 
deletion of 
CD97 promoter luciferase constructs 
 
pGL -3071/+45 (sense, –3071) cgg ggt acc tca aga aag ccg cca gga at 
pGL -2101/+45 (sense, –2101) gta ggt acc aga ctt gat ttc ggc atc ct 
pGL –1801/+45 (sense, –1801) tga ggt acc cat tgc aga tgt ttt gag ga 
pGL –1151/+45 (sense, –1151) tct ggt acc taa gtt tcc cac agg ggg aa 
pGL –218/+45 (sense, –218) tgt ggt acc atg cag cgc ccc tgg gtc tgt 
pGL -111/+45 (sense, -111) aat ggt acc ttc ata aag tcc tgg cct cg 
common (antisense, +45) cta gct agc cca gcg ggg ccc caa agt a 
For generation of oligonucleotides used 
for EMSA 
 
 GC-site (1)  wt agc ggc tgt ccg ccc ccc ctc c 
GC-site (1) mut agc ggc tgt aaa aaa aac ctc c 
GC-site (2)  wt aag acc gcc ccg ccc ggc tgc c 
GC-site (2)  mut aag acc gcc cca aac ggc tgc c 
GC-site (3)  wt cac cac aac ctc cgc ctc ctg g 
GC-site (3)  mut cac cac aac ctc caa atc ctg g 
GC-site (4)  wt ggg act ctg ggg ctg ggc tgc c 
GC-site (4)  mut ggg act cta aaa aaa aaa tgc c 
GC-site (5)  wt gtg ttc att ccc ctc ccc cac a 
GC-site (5) mut gtg ttc att aaa aaa aaa cac a 
GC-consenus sequence att cga tcg ggg cgg ggc gag c 
For site-directed mutagenesis of GC-
sites in CD97 promoter luciferase 
constructs 
 
GC-site (1) sense ggc cag cgg ctg tcc aaa ccc cct cct tca taa agt 
GC-site (1) antisense act tta tga agg agg ggg ttt gga cag ccg ctg gcc 
GC-site (2) sense agg caa gac cgc ccc aaa cgg ctg cca cac ctt c 
GC-site (2) antisense gaa ggt gtg gca gcc gtt tgg ggc ggt ctt gcc t 
GC-site (3) sense cag ctc acc aca acc tcc aaatcc tgg gtt cta tca gtc c 
GC-site (3) antisense gga ctg ata gaa ccc agg att tgg agg ttg tgg tga gct g
GC-site (4) sense cat tgt agg gac tct gga aat ggg ctg ccc gcc tat gg 
GC-site (4) antisense cca tag gcg ggc agc cca ttt cca gag tcc cta caa tg 
GC-site (5) sense tgg tgt tca ttc ccc taa acc aca gcc cag gcc acc 
GC-site (5) antisense ggt ggc ctg ggc tgt ggt tta ggg gaa tga aca cca 
For amplification after ChIP  
GC-site (1) sense atg cag cgc ccc tgg gtc tgt 
GC-site (1) antisense aag agt gag tgg gac agg gc 
GC-site (2) sense gct att tct gac aag acc cc 
GC-site (2) antisense tgc act cag taa gaa tgg agt 
GC-site (3) sense tgc ccg cct atg gat ct 
GC-site (3) antisense tat ttc aga ggc ctc ttc gt 
GC-site (4) sense agt aag gca cag tca tct at 
GC-site (4) antisense cag tgt gag aga aaa gat aa 
GC-site (5) sense ttc cag cgg gga gga cag tt 
GC-site (5) antisense ccc ttc ctg tcc tgg gct cc 
Italic letters indicate the positions that carry mutations. 
 
Tab. 2: Sp1/Sp3 sites in the sequence (3071 nt) upstream of the translation start site of the human CD97 gene predicted with different methods. The 
position in the column head indicates the first nucleotide of the triplet mutated to  'AAA' in site mutation studies. 
 
 
mutated position -122     -392 -1392 -1888 -2317 others
sequence TGTCCGCCCCCC GCCCCGCCCG CTCCCGCCTC GGGGCTGGGC TCCCCTCCCC  
Patch (public 1.0) 
database = TRANSFAC 6.0 
sites searched for = vertebrates 
maximum number of mismatches = 0 
mismatch penalty = 100 
lower score boundary = 87.5 
√ √ √ √ √ 0 
Match (public 1.0) 
database = TRANSFAC 6.0 
matrix similarity = 0.9 
core similarity = 0.75 
√ √ - √ √ 7 
pwmatch 
database = TRANSFAC 6.0 licensed 
motiflist = M00008, M00196 
M00931, M00932, M00933, M00665 
      
score = 0.8 √ √ √ √ √ 8 
score = 0.85 √ √ - √ √ 4 
pwmatch 
Database = JASPAR 2005 
Motiflist = MA0079 
      
score = 0.8 √ √ - √ √ 7 
score = 0.85 - - - √ -  3
 
TCCCCTCCCC GGGGCTGGGC CTCCGCCTC GCCCCGCCCG TGTCCGCCCCCC
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